WD Repeat and Coiled Coil Containing Protein
WDCP | |||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
Aliases | WDCP, C2orf44, PP384, WD repeat and coiled coil containing, MMAP | ||||||||||||||||||||||||||||||||||||||||||||||||||
External IDs | OMIM: 616234; MGI: 3040699; HomoloGene: 49822; GeneCards: WDCP; OMA:WDCP - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
WD Repeat and Coiled-coiled containing protein (WDCP) is a protein which in humans is encoded by the WDCP gene. The function of the protein is not completely understood, but WDCP has been identified in a fusion protein with anaplastic lymphoma kinase found in colorectal cancer.[5] WDCP has also been identified in the MRN complex, which processes double-stranded breaks in DNA.[6]
Gene
[edit]WDCP is located in chromosome 2, specifically locus 2p23.3 on the minus strand, in humans. The total gene is 20,235 bp long, from 24,029,340 – 24,047,575. WDCP is located in between the MFSD2B and FKBP1B genes.[7] The total gene contains 4 exons, the details of which can be seen in the table below.[8]
Exon Number | Length (bp) | Start and End Positions |
---|---|---|
Exon 1 | 78 | 24047393-24047343 |
Exon 2 | 1836 | 24039512-24037677 |
Exon 3 | 118 | 24032946-24032829 |
Exon 4 | 1816 | 24031162-24029347 |
Table 1. Exons of WDCP and their various lengths.
Common aliases of the gene include chromosome 2, open reading frame 44 (c2orf44), MMAP, and PP384.[9]
mRNA
[edit]The WDCP isoform 1 is encoded by mRNA-WD repeat and coiled-coil containing, transcript variant 1. The total RNA transcript is 18,045 bp long and is transcribed from the WDCP gene from nucleotides 24,029,347 - 24,047,391.[9] The coding DNA sequence is 3848 nucleotides long. The 5’ UTR contains 7,897 nucleotides, and the 3’ UTR contains 1,597 nucleotides.
There are two known transcript variants of WDCP: WDCP transcript variant 2 and WDCP transcript variant X1. Information about the two transcripts can be seen below.[8]
Transcript Variant | Accession Number [9] | Alternative Splicing Pattern | Transcript Length (bp) | 5' UTR Length | 3' UTR Length |
---|---|---|---|---|---|
WDCP Transcript Variant 2 [10] | NP_001142319 | Removal of Exon 3 | 1869 | 7932 | 1776 |
WDCP Transcript Variant X1 [11] | XM_017005029 | Removal of Exon 4 | 2039 | 96 | 89 |
Table 2. Transcript Variants of WDCP with their alternative splicing pattern in comparison to WDCP transcript variant 1.
Protein
[edit]Primary sequence
[edit]WDCP protein isoform 1 is 721 amino acids in length. Its molecular weight is 79 kDa and the theoretical isoelectric point is 6.2.[12] The protein sequence for WDCP Protein Isoform 1 is shown below.[13]
1 MELGKGKLLR TGLNALHQAV HPIHGLAWTD GNQVVLTDLR LHSGEVKFGD SKVIGQFECV 61 CGLSWAPPVA DDTPVLLAVQ HEKHVTVWQL CPSPMESSKW LTSQTCEIRG SLPILPQGCV 121 WHPKCAILTV LTAQDVSIFP NVHSDDSQVK ADINTQGRIH CACWTQDGLR LVVAVGSSLH 181 SYIWDSAQKT LHRCSSCLVF DVDSHVCSIT ATVDSQVAIA TELPLDKICG LNASETFNIP 241 PNSKDMTPYA LPVIGEVRSM DKEATDSETN SEVSVSSSYL EPLDLTHIHF NQHKSEGNSL 301 ICLRKKDYLT GTGQDSSHLV LVTFKKAVTM TRKVTIPGIL VPDLIAFNLK AHVVAVASNT 361 CNIILIYSVI PSSVPNIQQI RLENTERPKG ICFLTDQLLL ILVGKQKLTD TTFLPSSKSD 421 QYAISLIVRE IMLEEEPSIT SGESQTTYST FSAPLNKANR KKLIESLSPD FCHQNKGLLL 481 TVNTSSQNGR PGRTLIKEIQ SPLSSICDGS IALDAEPVTQ PASLPRHSST PDHTSTLEPP 541 RLPQRKNLQS EKETYQLSKE VEILSRNLVE MQRCLSELTN RLHNGKKSSS VYPLSQDLPY 601 VHIIYQKPYY LGPVVEKRAV LLCDGKLRLS TVQQTFGLSL IEMLHDSHWI LLSADSEGFI 661 PLTFTATQEI IIRDGSLSRS DVFRDSFSHS PGAVSSLKVF TGLAAPSLDT TGCCNHVDGM 721 A
Figure 1. Protein sequence of WDCP protein isoform 1.
Compositional analysis of WDCP Isoform 1 shows no extremely high or low levels of particular amino acids. The protein contains no positive, negative, or mixed charged clusters. [14]
There are two isoforms of WDCP, as seen in the table below.
Isoform Name | Accession No. | Length (aa) | Molecular Weight [12] | Isoelectric Point [12] |
---|---|---|---|---|
WDCP Protein Isoform 2 [15] | NP_001135791 | 622 | 69 | 6.5 |
PREDICTED: WDCP Protein Isoform X1 [16] | XP_016860518 | 617 | 68 | 6.4 |
Table 3. Table of WDCP protein Isoforms and Protein Information.
Secondary structure
[edit]The secondary structure of WDCP Protein Isoform 1 consists of 47 random coils (429 residues, 59.5%), 19 alpha-helices (160 residues, 22.19%), and 31 extended strands (132 residues, 18.31%).[17]
Tertiary and quaternary structure
[edit]There are two predicted disulfide bonds in WDCP, one between cysteine residues 574 and 623, and the other between cysteine residues 713 and 714.[18]
Domains and motifs
[edit]WDCP protein domains include two tryptophan-aspartic acid repeat sites, multiple phosphorylation sites, and a domain that interacts with the hemopoietic cell kinase.[19]
Tissue expression
[edit]Across various tissue types, WDCP shows increased mRNA expression in white blood cells (3.0 RPKM), thymus (3.6 RPKM), lymph nodes, bone marrow, and testes.[9] WDCP exhibits increased protein expression in endocrine tissues, and well as the kidney and urinary bladder.[20] Across multiple tissue lines in the GTEx database, WDCP expression seemed to be highest in Epstein-Barr Virus transformed lymphocytes and lowest in the pancreas.[21] NCBI GEO Records reveal that overall WDCP expression is in the 65-70th percentile according to the Universal Human Reference RNA.[22]
In fetal tissue, WDCP mRNA expression is highest in the lung at 17 weeks at 3.75 RPKM, the heart at 10 weeks at 3.5 RPKM, and in the intestine at 11 weeks 3.0 RPKM. At 17 weeks, WDCP expression in the intestine drops down from 3.0 RPKM to 0.75 RPKM. The fetal kidney at 20 weeks exhibits the lowest WDCP expression, at 0.5 RPKM.[9]
Regulation of expression
[edit]Epigenetic
[edit]WDCP does not have any CpG islands associated with its promoter. WDCP has relatively low levels of H3K27ac, but higher levels of H3K4me1 and H3K4me3 across various cell types, including HeLa, HUVEC, and leukemia cell lines.[8]
Transcriptional
[edit]The GeneHancer promoter for WDCP is listed as GH02J024045. The transcription factor binding sites associated with this promoter and confirmed with a ChIP signal include HNF4A, CEBPB, ERG1, FOS1, ETS1, and E2F6.[8] The binding sites for FOS, EGR1, and ETS1 are located in a DNase hypersensitive site.
Post-transcriptional
[edit]There are two transcript variants of WDCP detailed in the table in the mRNA section.
Translational and mRNA stability
[edit]The mRNA secondary structures of the UTR regions exhibited a high number of predicted stem-loop structures in the WDCP transcript. The 5' UTR region closest to the start codon contained about 22 predicted loops. Stem loops in the 5' UTR near the start codon could indicate lower levels of expression.[23] There are 108 predicted loops in the 3' UTR region.[24] There are no known miRNA targets in the 3' UTR.
Post-translational modifications
[edit]![](http://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WDCP_wiki_conceptual_tln_the_end.png/600px-WDCP_wiki_conceptual_tln_the_end.png)
WDCP Isoform 1 contains the following post-translational modifications:
Glycation is the addition of a sugar molecule to an amino acid and is associated with pathologies including renal failure and diabetes.[25] Glycation is predicted to occur at lysine residues: 5, 7, 83, 189, 244, 262, 294, 325, 389, 405, 407, 461, 552, and 617.
Acetylation is the addition of an acetyl group at the starting methionine residue. This is usually associated with metabolic-relating pathways. WDCP has one confirmed acetylation site at the starting methionine residue.[26]
Phosphorylation is the addition of a phosphate group to amino acids. It is mainly associated with cellular signaling pathways and can instigate tumor development. Serine, Threonine, and Tyrosine phosphorylation sites were identified in 27 residues at a NetPhos threshold of 0.9.[27] Phosphorylation was detected at:
- Serine residues 43, 97, 147, 181, 267, 274, 278, 416, 417, 441, 504, 505, 528, 529, 535, 550, 590, 630, 676, 678, 686, 688, and 690.
- Threonine residues 73 and 385.
- Tyrosine residues 422 and 555.
Possible kinases that interact with WDCP include Casein kinase 1, Casein kinase 2, cAMP, cGMP, P38MAPK, DNAPK, Protein kinase A, and Protein kinase C.[27]
SUMOylation is the addition of a small ubiquitin-like modifier to lysine residues in proteins. SUMOYlation sites in WDCP include lysine residues 47, 152, 298, 310, 709, with lysine residues 47 and 152 having the highest probability of SUMOylation.[28] SUMOylation can affect protein-protein interactions and affect protein ubiquitination.[29]
Palmitoylation is the addition of a fatty acid chain to cysteine residues. There is one confirmed site of palmitoylation at cysteine residue 714.[30]
GalNAc O-Glycosylation is the addition of a sugar molecule to a serine or threonine residue, which possibly increases structural stability.[31] Some of these residues overlap with phosphorylation sites, indicating that these residues can switch between a phosphorylation site.[32][33] These sites were detected at:
- Serine residues 137, 243, 267, 271, 274, 295, 485, 528, 529, 688, and 695. Sites 267, 274, 528, 529, and 688 overlap with a phosphorylation site.
- Threonine residues 412, 440, 447, 484, 534.
N-glycosylation is the addition of a sugar molecule to an asparagine residue. Asparagine residue 483 is the only detected N-glycosylation site in WDCP.[34]
There were no sites of amidation, C-linked mannosylation, GPI modification sites, non-classical protein secretion, transmembrane helices or regions, prediction of R and K cleavage sites, lipoprotein sites, sulfonated tyrosines, or Twin Arginine signal peptides.[35]
Subcellular localization
[edit]WDCP Isoform 1 has no transmembrane domains, actin-binding motifs, ER retention motifs, or Golgi transport signals. The protein is most likely located in the nucleus, with a reliability score of 47.8%, and a 30.4% chance of being located in the cytoplasm.[36][37] Close orthologs of WDCP Isoform 1 have shown similar results for orthologous proteins, where the protein is most likely located in the nucleus.[37] In addition, there are two predicted nuclear localization sequences in WDCP, starting at residues 401 and 581.[38]
Immunostaining of WDCP has shown localization in the nucleoli of osteosarcoma cells, as well as the cytoplasm of kidney cells.[39]
Function
[edit]The function of WDCP is currently not well-understood, but due to increased expression levels in the bone marrow and thymus, the protein could have possible relations to immune function and development. Its location in the nucleus, relation to the MRN complex, an abundance of phosphorylation sites, and associations with various cancers could indicate a role in cell growth regulation or a proto-oncogenic function.
Interacting proteins
[edit]WDCP has known interactions with HCK, where a proline-rich region of WDCP binds to the Src homology 3 domain of HCK. As mentioned before, WDCP was known to exist in a fusion with ALK. This fusion changes the structure of ALK, which results in constitutive signaling.[40]
Studies have confirmed interactions between WDCP and RuvB-like proteins 1 and 2 in human embryonic kidney cells, which belong to a family of AAA proteins associated with ATPase activity, C1q and tumor necrosis factor related protein 2 and DYNLT1.[41][42][43]
Based on the transcription factor binding sites listed in the transcriptional regulation section, WDCP could have possible interactions with the following transcription factors:
- HNF4A: Elevations in expression levels are associated with colorectal cancer.[44]
- CEBPB: Involved in regulating immune responses[45]
- EGR1: Tumor suppressor gene involved with neuronal plasticity and memory formation [46][47]
- FOS: Proto-oncogene associated with osteosarcomas.[48]
- ETS1: Aids in pathogen and tumor defense.[49]
- E2F6: Associated with the oncogenic Bmi1 polycomb complex.[50]
Clinical significance
[edit]Studies have linked WDCP to various cancers, including colorectal cancer, leukemia, and osteosarcomas. WDCP levels are higher in colorectal cancer metastases compared to the primary tumor.[51] GEO Records show elevated levels of WDCP in leukemia cell lines, which are regulated with Imatinib, a drug used to treat chronic myelogenous leukemia.[52] This pattern is also seen in HeLa cell lines when treated with Casiopenias, small molecules with an active Cu2+ that allow the molecule to bind to tumors and induce apoptosis.[53][54]
Homology
[edit]![](http://upload.wikimedia.org/wikipedia/commons/thumb/b/b7/Homology_Graph.jpg/600px-Homology_Graph.jpg)
There are no paralogs of WDCP, but orthologs of this gene were found in primates, rodents, reptiles, birds, fish, amphibians, echinoderms, and possibly fungi. There are no orthologs in prokaryotes or plants. There were no organisms with proteins containing homologous domains.[55]
The graph to the right shows the rate of evolution of WDCP in comparison to the evolution rate of the fibrinogen alpha-chain (NCBI: NP_068657) and cytochrome c (NCBI: NP_061820). As seen in the graph to the right, the evolution rate of WDCP is faster than that of cytochrome c, but slower than the evolution of the fibrinogen alpha-chain.
While there are some sequences in WDCP that are conserved (which can be seen in the conceptual translation), there are very few known conserved domains among the various orthologs. There is one conserved glycation site detected through a multiple sequence alignment, lysine 389.[56] The table below shows a list of orthologs, the evolutionary date of divergence between the organism and humans, and the % identity between WDCP Isoform 1 and the orthologous protein sequence.
Organism | Accession number [55] | Date of divergence (MYA)[57] | % ID (compared to Homo sapiens) |
---|---|---|---|
Chimpanzee | XP_001143574 | 6 | 99 |
Rhesus monkey | NP_001181022.2 | 29 | 95 |
Mouse | NP_001164329.1 | 89 | 65 |
Common wall lizard | XP_028578194 | 318 | 51 |
Crested ibis | XP_009465592 | 324 | 51 |
Central bearded dragon | XP_020643724 | 318 | 49 |
African clawed frog | NP_001090236 | 352 | 51 |
Barn owl | KFV58830 | 318 | 49 |
Whale shark | XP_020374495 | 465 | 48 |
Zebrafish | NP_001013552 | 433 | 46 |
Tropical clawed frog | XP_017949975 | 352 | 40 |
Black-legged tick | XP_022781485.1 | 736 | 29 |
Octopus | XP_029634208 | 736 | 27 |
Table 4. Table of organisms with a WDCP orthologous protein.
Notes
[edit]- ^ a b c GRCh38: Ensembl release 89: ENSG00000163026 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000051721 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Yakirevich E, Resnick MB, Mangray S, Wheeler M, Jackson CL, Lombardo KA, et al. (August 2016). "Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target". Clinical Cancer Research. 22 (15): 3831–40. doi:10.1158/1078-0432.ccr-15-3000. PMID 26933125.
- ^ "WDCP Gene". GeneCards. GeneCards Suite. Retrieved 28 April 2020.
- ^ "Gene: WDCP (ENSG00000163026) - Summary - Homo sapiens - Ensembl genome browser 89". may2017.archive.ensembl.org. Retrieved 3 May 2020.
- ^ a b c d "UCSC Genome Browser Entry on WDCP gene in humans". UCSC Genome Browser. University of California, Santa Cruz. Retrieved 19 April 2020.
- ^ a b c d e "WDCP WD repeat and coiled coil containing [ Homo sapiens (human) ]". National Center for Biotechnology Information. NIH. Retrieved 29 April 2020.
- ^ "WD repeat and coiled-coil-containing transcript variant (Homo sapiens)". National Center for Biotechnology Information. National Institutes of Health. May 2020. Retrieved 3 May 2020.
- ^ "PREDICTED: Homo sapiens WD repeat and coiled coil containing (WDCP), transcript variant X1, mRNA". National Center for Biotechnology Information. National Institute of Health. 2 March 2020. Retrieved 3 May 2020.
- ^ a b c "Compute pI/MW tool". ExPASy. SIB Bioinformatics Resource Portal. Retrieved 3 May 2020.
- ^ "WD repeat and coiled-coil-containing protein isoform 1 [Homo sapiens]". National Center for Biotechnology Information. National Institute of Health. Retrieved 3 May 2020.
- ^ "SAPS < Sequence Statistics < EMBL-EBI". www.ebi.ac.uk. EMBL-EBI. Retrieved 3 May 2020.
- ^ "WD repeat and coiled-coil containing protein isoform 2". National Center for Biotechnology Information. National Institute of Health. Retrieved 3 May 2020.
- ^ "WD repeat and coiled-coil-containing protein isoform X1 [Homo sapiens]". National Center for Biotechnology Information. National Institute of Health. Retrieved 3 May 2020.
- ^ "abi GOR IV Protein Secondary Structure Prediction Method". Rhone-Alpes Bioinformatic Pole Gerland Site. Prabi-Gerland. Retrieved 3 May 2020.
- ^ "DISULFIND - Cysteines Disulfide Bonding State and Connectivity Predictor". disulfind.dsi.unifi.it. Retrieved 3 May 2020.
- ^ "WD repeat and coiled-coil-containing protein isoform 1 [Homo sapiens]". National Center for Biotechnology Information. National Institute of Health. Retrieved 19 April 2020.
- ^ Human Protein Atlas Entry on WDCP
- ^ "GTEx Expression for WDCP". GTEx Portal. Retrieved 3 May 2020.
- ^ "GDS3113 Records on WDCP Expression in Various Normal Tissues / 116986". www.ncbi.nlm.nih.gov. Retrieved 3 May 2020.
- ^ Lamping E, Niimi M, Cannon RD (July 2013). "Small, synthetic, GC-rich mRNA stem-loop modules 5' proximal to the AUG start-codon predictably tune gene expression in yeast". Microbial Cell Factories. 12 (1): 74. doi:10.1186/1475-2859-12-74. PMC 3765126. PMID 23895661.
- ^ "Displaying 15/20May03-15-15-53/20May03-15-15-53_1.jpg". unafold.rna.albany.edu. SUNY Albany. Retrieved 3 May 2020.
- ^ Wautier, J.-L., & Schmidt, A. M. (2004). Protein Glycation. Circulation Research, 95(3), 233–238. doi: 10.1161/01.res.0000137876.28454.64
- ^ "Terminus". exPASy. SIB Bioinformatics Portal. Retrieved 3 May 2020.
- ^ a b "NetPhos 3.1 Server". DTU Bioinformatics. Department of Bio and Health Informatics. Retrieved 3 May 2020.
- ^ "SUMOplot Analysis Program". Abcepta. Retrieved 3 May 2020.
- ^ Wilkinson KA, Henley JM (May 2010). "Mechanisms, regulation and consequences of protein SUMOylation". The Biochemical Journal. 428 (2): 133–45. doi:10.1042/BJ20100158. PMC 3310159. PMID 20462400.
- ^ "CSS-Palm. Prediction of Palmitoylation Site". CSS-Palm. Prediction of Palmitoylation Site. The Cuckoo WorkGroup. Archived from the original on 15 February 2009. Retrieved 3 May 2020.
- ^ Van den Steen P, Rudd PM, Dwek RA, Opdenakker G (1 January 1998). "Concepts and principles of O-linked glycosylation". Critical Reviews in Biochemistry and Molecular Biology. 33 (3): 151–208. doi:10.1080/10409239891204198. PMID 9673446.
- ^ "NetOGlyc 4.0 Server". DTU Bioinformatics. Department of Bio and Health Informatics. Retrieved 3 May 2020.
- ^ "YinOYang 1.2". DTU Bioinformatics. Department of Bio and Health Informatics. Retrieved 3 May 2020.
- ^ "NetNGlyc". DTU Bioinformatics. Department of Bio and Health Informatics. Retrieved 3 May 2020.
- ^ "Proteomics". exPASy. SIB Bioinformatics Resource Portal. Retrieved 3 May 2020.
- ^ "SOSUI". SOSUI.
- ^ a b "PSORT II Prediction". exPASy. SIB Bioinformatics Portal. Retrieved 3 May 2020.
- ^ Kosugi, Shunichi. "cNLS Mapper". cNLS Mapper. Archived from the original on 22 November 2021. Retrieved 3 May 2020.
- ^ "C2orf44 Antibody (PA5-59410)". www.thermofisher.com. Retrieved 29 April 2020.
- ^ Yokoyama N, Miller WT (January 2015). "Molecular characterization of WDCP, a novel fusion partner for the anaplastic lymphoma tyrosine kinase ALK". Biomedical Reports. 3 (1): 9–13. doi:10.3892/br.2014.374. PMC 4251150. PMID 25469238.
- ^ Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, et al. (2007). "Large-scale mapping of human protein-protein interactions by mass spectrometry". Molecular Systems Biology. 3: 89. doi:10.1038/msb4100134. PMC 1847948. PMID 17353931.
- ^ Huttlin EL, Bruckner RJ, Paulo JA, Cannon JR, Ting L, Baltier K, et al. (May 2017). "Architecture of the human interactome defines protein communities and disease networks". Nature. 545 (7655): 505–509. Bibcode:2017Natur.545..505H. doi:10.1038/nature22366. PMC 5531611. PMID 28514442.
- ^ Cloutier P, Poitras C, Durand M, Hekmat O, Fiola-Masson É, Bouchard A, et al. (May 2017). "R2TP/Prefoldin-like component RUVBL1/RUVBL2 directly interacts with ZNHIT2 to regulate assembly of U5 small nuclear ribonucleoprotein". Nature Communications. 8: 15615. Bibcode:2017NatCo...815615C. doi:10.1038/ncomms15615. PMC 5460035. PMID 28561026.
- ^ Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, et al. (September 2014). "Proteogenomic characterization of human colon and rectal cancer". Nature. 513 (7518): 382–7. Bibcode:2014Natur.513..382.. doi:10.1038/nature13438. PMC 4249766. PMID 25043054.
- ^ "CEBPB CCAAT enhancer binding protein beta [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. National Institutes of Health.
- ^ "EGR1 early growth response 1 [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. National Institutes of Health.
- ^ Knapska E, Kaczmarek L (November 2004). "A gene for neuronal plasticity in the mammalian brain: Zif268/Egr-1/NGFI-A/Krox-24/TIS8/ZENK?". Progress in Neurobiology. 74 (4): 183–211. doi:10.1016/j.pneurobio.2004.05.007. PMID 15556287. S2CID 39251786.
- ^ Wang ZQ, Liang J, Schellander K, Wagner EF, Grigoriadis AE (December 1995). "c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos". Cancer Research. 55 (24): 6244–51. PMID 8521421.
- ^ Gallant S, Gilkeson G (2006). "ETS transcription factors and regulation of immunity". Archivum Immunologiae et Therapiae Experimentalis. 54 (3): 149–63. doi:10.1007/s00005-006-0017-z. PMID 16652219. S2CID 10512011.
- ^ Trimarchi, Jeffrey M.; Fairchild, Brian; Wen, Jessica; Lees, Jacqueline A. (13 February 2001). "The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex". Proceedings of the National Academy of Sciences. 98 (4): 1519–1524. Bibcode:2001PNAS...98.1519T. doi:10.1073/pnas.98.4.1519. ISSN 0027-8424. PMC 29289. PMID 11171983.
- ^ "GDS1780 Records of WDCP: Colorectal cancer progression: polysomal mRNA profiles". NCBI GEO. National Institute of Health. Retrieved 3 May 2020.
- ^ "GDS3048 Record on WDCP". NCBI GEO. National Institute of Health. Retrieved 29 April 2020.
- ^ "GDS4665 Records on WDCP: HeLa cell line response to chemotherapeutic Casiopeinas". NCBI GEO. National Institute of Health. Retrieved 3 May 2020.
- ^ Mejia C, Ruiz-Azuara L (December 2008). "Casiopeinas IIgly and IIIia induce apoptosis in medulloblastoma cells". Pathology & Oncology Research. 14 (4): 467–72. doi:10.1007/s12253-008-9060-x. PMID 18521723. S2CID 28722785.
- ^ a b "Basic Local Alignment Search Tool". National Center for Biotechnology Information. National Institute of Health. Retrieved 31 March 2020.
- ^ "Clustal Omega < Multiple Sequence Alignment < EMBL-EBI". www.ebi.ac.uk. Retrieved 3 May 2020.
- ^ "TimeTree". TimeTree: The Timescale of Life. Temple University Institute for Genomics and Evolutionary Medicine Center of Biodiversity. Retrieved 3 May 2020.